Roivant Sciences (FRA:87S) FCF Margin %: -6,550.18% (As of Mar. 2026)


FRA:87S Roivant Sciences Ltd FRA:87S
55 GF Score
Price €30.01
GF Value €8.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences FCF Margin %?

Roivant Sciences FRA:87S +6.91% 55 FCF Margin % is -6,550.18% as of Mar. 2026. GuruFocus rates FRA:87S with a GF Score™ of 55/100 and a GF Value™ of €8.56 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 960 Biotechnology companies, Roivant Sciences ranks worse than 93.65% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Roivant Sciences's Free Cash Flow for the three months ended in Mar. 2026 was €-142.79 Mil. Roivant Sciences's Revenue for the three months ended in Mar. 2026 was €2.18 Mil. Therefore, Roivant Sciences's FCF Margin % for the quarter that ended in Mar. 2026 was -6,550.18%.

As of today, Roivant Sciences's current FCF Yield % is -3.09%.

The historical rank and industry rank for Roivant Sciences's FCF Margin % or its related term are showing as below:

FRA:87S' s FCF Margin % Range Over the Past 10 Years
Min: -9183.51   Med: -2529.97   Max: -1257.4
Current: -9174.6

During the past 6 years, the highest FCF Margin % of Roivant Sciences was -1257.40%. The lowest was -9183.51%. And the median was -2529.97%.

FRA:87S's FCF Margin % is ranked worse than
93.65% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs FRA:87S: -9174.60

Roivant Sciences FCF Margin % Related Terms

Roivant Sciences FCF Margin % Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences FCF Margin % Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
FCF Margin %
Get a 7-Day Free Trial -1,257.39 -2,715.14 -2,343.56 -2,905.21 -9,183.39

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,290.39 -9,606.49 -12,322.27 -9,583.07 -6,550.18

FRA:87S vs INSM, INCY, BNTX: FCF Margin % Comparison

For the Biotechnology subindustry, Roivant Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roivant Sciences FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's FCF Margin % falls into.


FRA:87S
55GF Score
Roivant Sciences Ltd FRA:87S
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Roivant Sciences's FCF Margin for the fiscal year that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-656.153/7.145
=-9,183.39 %

Roivant Sciences's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-142.794/2.18
=-6,550.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -6,550.18% mean?
Roivant Sciences (FRA:87S) has a FCF Margin % of -6,550.18% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Roivant Sciences and its competitors. According to the industry distribution chart, Roivant Sciences ranks #899 out of 960 companies in the Biotechnology industry, placing it in the top 93.6%.
Is Roivant Sciences' FCF Margin % too high?
Roivant Sciences' current FCF Margin % is -6,550.18%. Based on the distribution chart, Roivant Sciences ranks #899 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' FCF Margin % compare to INSM and INCY?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #899 out of 960 companies for FCF Margin %. This places Roivant Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current FCF Margin % is -6,550.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (FRA:87S) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.56, compared to a current price of €30.01 — trading 250.6% above its estimated fair value. The current FCF Margin % is -6,550.18%. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Roivant Sciences (FRA:87S), the current FCF Margin % is -6,550.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roivant Sciences (FRA:87S) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of €30.01 is trading 250.6% above its estimated GF Value™ of €8.56. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for FRA:87S:

  • FCF Margin %: -6,550.18%
  • GF Value™: €8.56 vs. price of €30.01 (250.6% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FRA:87S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for FRA:87S

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.01
Price
€8.56
GF Value